Aluda Pharmaceuticals, Inc.
Aluda Pharmaceuticals develops novel small molecule therapeutics for severe immune and fibrotic diseases, utilizing a systems biology approach targeting under-recognized and complex disease mechanisms. The company focuses on discovery and development of new molecular entities aimed at key regulatory proteins such as vimentin and STAT3, leveraging expertise in phenotypic screening, network-driven biology, and translational science. Aluda's pipeline addresses unmet needs in autoimmune, fibrotic, and refractory cancer conditions, with a scientific foundation in deep cell biology and state-of-the-art discovery methods.
Industries
N/A
Aluda Pharmaceuticals, Inc.
1080 Marsh Road, Suite 200, Menlo Park, CA 94025
Patents
2,4,6-trisubstituted s-triazine compound, preparation method therefor, and use thereof
2022-07-19 • US-11390591-B2
View Details2,4,6-trisubstituted s-triazine compound, preparation method therefor, and use thereof
2020-04-07 • US-10611736-B2
View Details
2,4,6-trisubstituted s-triazine compound, preparation method therefor, and use thereof
2022-07-19 • US-11390591-B2
View Details2,4,6-trisubstituted s-triazine compound, preparation method therefor, and use thereof
2020-04-07 • US-10611736-B2
View DetailsProducts
Oral small molecules developed to modulate vimentin, aimed at treating immune/fibrotic diseases, cancer signaling, and severe infections.
Proprietary compounds targeting specific STAT3 variants for modulation of immune and cancer pathways.
Compounds targeting host cellular scaffolds required by viruses, bacteria, and fungi for cellular entry, replication, or egress, to reduce infection and immune overstimulation.
Oral small molecules developed to modulate vimentin, aimed at treating immune/fibrotic diseases, cancer signaling, and severe infections.
Proprietary compounds targeting specific STAT3 variants for modulation of immune and cancer pathways.
Compounds targeting host cellular scaffolds required by viruses, bacteria, and fungi for cellular entry, replication, or egress, to reduce infection and immune overstimulation.
Expertise Areas
- Immunology drug discovery
- Translational research in severe immune/fibrotic disease
- Systems biology and network pharmacology
- Preclinical validation in autoimmune, fibrotic, and cancer models
Key Technologies
- Phenotypic screening platforms
- CRISPR gene editing
- Proteomics
- Network/pathway analysis
Key People
Founder and CEO
Founder and Chief Medical Officer
Founder and COO
Founder and CEO
Founder and Chief Medical Officer
Founder and COO
News & Updates
Chosen as one of ten start-ups for the CLS FAST Fall 2023 cohort, receiving mentoring from executives in biotech and pharma.
Featured for advances in targeting vimentin for fibrosis.
Peer-reviewed article describing vimentin modulation as a therapeutic intervention in sepsis.
Publication by collaborator Dr. Annica Gad providing new evidence for vimentin’s role in EMT as targetable in lung cancer.
Article profiling compound effects on vimentin filament properties and cell behavior.
Paper evidencing effects on COVID-19 and related diseases.
Chosen as one of ten start-ups for the CLS FAST Fall 2023 cohort, receiving mentoring from executives in biotech and pharma.
Featured for advances in targeting vimentin for fibrosis.
Peer-reviewed article describing vimentin modulation as a therapeutic intervention in sepsis.
Publication by collaborator Dr. Annica Gad providing new evidence for vimentin’s role in EMT as targetable in lung cancer.
Article profiling compound effects on vimentin filament properties and cell behavior.
Paper evidencing effects on COVID-19 and related diseases.